Zolafren 5mg 30 tablets — Made in Poland by Adamed — Free Delivery

Zolafren tablets are indicated for:

Active ingredient: 1 tablet contains 5 mg or 10 mg of olanzapine;

Excipients: lactose, microcrystalline cellulose, sodium starch (type A), magnesium stearate;

Shell: hypromellose (hypromellose), polyethylene glycol (Macrogol) 400, Yellow No.6 Al-Lake dye (E 110), titanium dioxide (E 171), iron oxide yellow (E172), lactose.

Hypersensitivity to the active substance or to the auxiliary components of the preparation.

Known risk of angle-closure glaucoma.

Treatment of schizophrenia, manic episodes and prevention of relapse in bipolar disorder. The daily dose to be determined based on clinical status in the range of 5 to 20 mg per day. An increase in the recommended initial dose should be carried out at intervals of at least 24 hours only after a clinical examination. Olanzapine should be used with or without food, as food does not affect the absorption of the preparation. With the abolition of the preparation, the end of therapy should be carried out gradually.

Olanzapine should be used during pregnancy only when the expected results justify the potential risk to the fetus.

Olanzapine is not recommended for the treatment of children and adolescents.

With caution, dizziness and drowsiness are possible.

Symptoms. Very common (> 10%): tachycardia, agitation/aggression, dysarthria, various extrapyramidal symptoms and decreased level of consciousness, ranging from sedation to coma.

Other significant complications of overdose are delirium, convulsions, coma, the possibility of neuroleptic malignant syndrome, respiratory depression, aspiration, arterial hypertension or hypotension, cardiac arrhythmias (<2% of overdose cases) and cardiopulmonary shock. Fatal outcomes have been reported with acute overdose at the 450 mg level, but there have been cases of survival after acute overdose after taking 2 g of olanzapine orally.

Treatment. There is no specific antidote. Preparations that cause vomiting are not recommended. Recommended standard procedures for overdose (for example, gastric lavage, activated charcoal). Co-administration of activated charcoal has been found to reduce oral bioavailability of olanzapine by 50-60%.

The most common adverse reactions (observed in ≥ 1% of patients) associated with the use of olanzapine in clinical studies were: drowsiness, weight gain, eosinophilia, increased levels of prolactin, cholesterol (cholesterol), glucose and triglycerides in the blood, glycosuria, increased appetite, dizziness, akathisia, parkinsonism, leukopenia, neutropenia, dyskinesia, orthostatic hypotension, anticholinergic effects, transient asymptomatic increase in hepatic transaminases, rash, asthenia, fatigue, hyperthermia, arthralgia, elevated levels of alkaline phosphatase, gammaglutamyltransferase, uric acid, CPK, and edema .

Caution should be exercised when olanzapine is administered with other preparations known to increase the QTc interval.

Store at a temperature not exceeding 25°C, in the original packaging.

Keep out of the reach of children.

Shelf life - 3 years.